Endurant Capital Management LP grew its position in shares of Becton Dickinson and Co (NYSE:BDX) by 43.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,070 shares of the medical instruments supplier’s stock after buying an additional 6,069 shares during the quarter. Endurant Capital Management LP’s holdings in Becton Dickinson and were worth $4,296,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. Legacy Advisors LLC grew its stake in Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 490 shares during the last quarter. Amica Retiree Medical Trust grew its stake in Becton Dickinson and by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 390 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Becton Dickinson and during the fourth quarter worth about $109,000. FTB Advisors Inc. grew its stake in Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 290 shares during the last quarter. Finally, Advisors Preferred LLC bought a new stake in Becton Dickinson and during the fourth quarter worth about $126,000. 83.35% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the transaction, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Timothy M. Ring sold 176 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total transaction of $38,415.52. Following the completion of the transaction, the director now owns 170,688 shares in the company, valued at $37,256,069.76. The disclosure for this sale can be found here. Insiders sold 281,108 shares of company stock worth $61,321,396 over the last 90 days. 1.00% of the stock is currently owned by company insiders.
Several analysts have weighed in on BDX shares. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research note on Wednesday, January 3rd. Deutsche Bank set a $260.00 price objective on shares of Becton Dickinson and and gave the stock a “buy” rating in a research note on Friday, December 29th. Argus upped their price objective on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Bank of America reaffirmed a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday, January 19th. Finally, Morgan Stanley increased their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. Six analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $238.00.
Shares of Becton Dickinson and stock opened at $223.27 on Monday. Becton Dickinson and Co has a 52 week low of $175.66 and a 52 week high of $248.39. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. The company has a market cap of $59,443.96, a P/E ratio of 23.16, a PEG ratio of 1.62 and a beta of 1.18.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the business posted $2.33 earnings per share. Becton Dickinson and’s revenue was up 5.4% compared to the same quarter last year. analysts anticipate that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be issued a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a yield of 1.34%. Becton Dickinson and’s dividend payout ratio is currently 229.01%.
COPYRIGHT VIOLATION WARNING: “Becton Dickinson and Co (BDX) Shares Bought by Endurant Capital Management LP” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/19/becton-dickinson-and-co-bdx-shares-bought-by-endurant-capital-management-lp.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.